Search
HY10275
go.drugbank.com/drugs/DB05079ExperimentalHY10275 is a novel compound specifically designed to modulate two key neurobiological mechanisms that interfere with the sleeping process. … HY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are known to impact the ability to fall asleep and stay asleep.
Magnesium glycinate
go.drugbank.com/drugs/DB11189ApprovedInvestigationalMagnesium glycinate is a magnesium salt of glycine that is available as dietary supplements as a source of magnesium. It is used in the treatment of magnesium deficiency.
LErafAON
go.drugbank.com/drugs/DB04973InvestigationalPhase I/II trials commenced in March 2001 and were ongoing as of June 2003. … NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation
Liposomal prostaglandin E1
go.drugbank.com/drugs/DB05391InvestigationalThe liposomal formulation of PGE-1 changes the drug’s dynamics and improve its therapeutic index in ways that PGE-1 alone could not achieve. … Liposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent.
Isoconazole
go.drugbank.com/drugs/DB08943ApprovedIsoconazole is an azole antifungal drug that has similar effectiveness to clotrimazole in the treatment of foot and vaginal infections.
LLL-3348
go.drugbank.com/drugs/DB05771ExperimentalThe botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.
Ferric subsulfate
go.drugbank.com/drugs/DB13885ApprovedFerric subsulfate is a stypic or hemostatic agent that causes agglutination of surface proteins resulting in local hemostasis. It has the chemical formula Fe4(OH)2(SO4)5. … It is used after superficial skin biopsies.
Tesaglitazar
go.drugbank.com/drugs/DB06536InvestigationalTesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. … Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.
Botulinum toxin type B
go.drugbank.com/drugs/DB00042ApprovedThe protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex. … The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation and chromatography steps.